Intercalated erlotinib/chemotherapy shows mixed results in NSCLC
A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 30, 2013 Category: Cancer & Oncology Source Type: news
Intercalated erlotinib/chemotherapy shows mixed results in NSCLC
A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 30, 2013 Category: Cancer & Oncology Source Type: news
Molecular marker predicts patients most likely to benefit longest from 2 popular cancer drugs
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival - up to two years - among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors. The U.S. Food and Drug Administration-approved drugs, gefitinib (Iressa) and erlotinib (Tarceva), are prescribed for lung and pancreatic cancer patients but only a few who have mutations in the EGFR gene usually benefit with a prolonged reduction of tumor size... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 9, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC
Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 9, 2013 Category: Cancer & Oncology Source Type: news
Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC
Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - September 9, 2013 Category: Respiratory Medicine Source Type: news
Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC
Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 9, 2013 Category: Cancer & Oncology Source Type: news
Chemotherapy best second-line option for EGFR wild-type NSCLC
Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 5, 2013 Category: Cancer & Oncology Source Type: news
Afatinib effective in erlotinib/gefitinib-resistant NSCLC
Afatinib is effective when given to patients with non-small-cell lung cancer who have progressed during treatment with erlotinib and/or gefitinib, phase II trial results reveal. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - August 2, 2013 Category: Cancer & Oncology Source Type: news
Afatinib effective in erlotinib/gefitinib-resistant NSCLC
Afatinib is effective when given to patients with non-small-cell lung cancer who have progressed during treatment with erlotinib and/or gefitinib, phase II trial results reveal. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - August 2, 2013 Category: Cancer & Oncology Source Type: news
Intercalated regimen demonstrates first-line efficacy for advanced NSCLC
Administration of erlotinib in combination with chemotherapy is a viable first-line treatment strategy in patients with advanced non-small-cell lung cancer, results from FASTACT-2 suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - July 26, 2013 Category: Cancer & Oncology Source Type: news
Intercalated regimen demonstrates first-line efficacy for advanced NSCLC
Administration of erlotinib in combination with chemotherapy is a viable first-line treatment strategy in patients with advanced non-small-cell lung cancer, results from FASTACT-2 suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - July 26, 2013 Category: Cancer & Oncology Source Type: news
BioPlus Specialty Pharmacy Selected as a Specialty Pharmacy With...
BioPlus selected as a specialty pharmacy for the new Tarceva network; now authorized to dispense this oncology medication.(PRWeb June 27, 2013)Read the full story at http://www.prweb.com/releases/2013/6/prweb10863930.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 30, 2013 Category: Pharmaceuticals Source Type: news
Lung Cancer Molecular Testing - Who Should Be Tested For Epidermal Growth Factor Receptor Mutations?
One of the greatest advances in lung cancer treatment in recent years has been the use of medications that target epidermal growth factor mutations (EGFR mutations.) For people who test positive for this mutation, medications such as Tarceva (erlotinib) can extend survival and improve quality of life - all without the degree of side effects seen with other forms of chemotherapy....Read Full Post (Source: About.com Lung Cancer)
Source: About.com Lung Cancer - June 20, 2013 Category: Cancer & Oncology Source Type: news
Anti-Cancer Agent Tarceva, Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations in Japan
Please find attached a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - June 14, 2013 Category: Pharmaceuticals Source Type: news
